Bio-Rad Laboratories is expected to report third-quarter 2026 revenue of approximately $649.94 million and earnings per share of $2.61, as the stock trades at $365.00 against an average analyst price target of $335.00.
Investors are primarily watching for a recovery in the Life Science segment, which has recently struggled with soft demand from biopharmaceutical and academic customers.
The company has signaled that market stabilization is underway, and participants are eager to see if instrument sales and consumable volumes confirm a turning point in bioprocessing destocking. Additionally, the valuation of Bio-Rad’s substantial equity stake in Sartorius AG will be closely scrutinized for its impact on reported results and overall corporate portfolio value.